Brokers Set Expectations for XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceutical company will earn ($3.58) per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same period in the previous year, the company posted ($0.62) EPS.

Several other equities research analysts also recently issued reports on XENE. Evercore ISI initiated coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an “outperform” rating and a $55.00 price target for the company. The Goldman Sachs Group cut their price target on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Wells Fargo & Company lowered their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen cut Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. Finally, Royal Bank of Canada lowered their price objective on Xenon Pharmaceuticals from $58.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $54.82.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $32.16 on Tuesday. The business has a fifty day simple moving average of $32.75 and a two-hundred day simple moving average of $36.56. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $46.00. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -11.40 and a beta of 1.09.

Institutional Trading of Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of XENE. Caitong International Asset Management Co. Ltd bought a new position in shares of Xenon Pharmaceuticals in the first quarter worth $30,000. GF Fund Management CO. LTD. bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $63,000. Quarry LP bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $78,000. Magnetar Financial LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $210,000. Finally, Vident Advisory LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $212,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.